DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/2r4sgn\/psoriasis_thought<\/a>) has announced the addition of the \"Psoriasis Thought Leader Panel #22 2012-04\" report to their offering. <\/p>\n Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development. <\/p>\n The Panel Weighs in On: <\/p>\n - The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals. <\/p>\n - Increases and decreases in cardiovascular events associated with inhibitors of TNF, IL23, IL17 and IL12. <\/p>\n - Advantages\/disadvantages of IL23\/IL12 vs p19 inhibitors. <\/p>\n - Advantages of a pure IL12 inhibitor <\/p>\n - Advantages\/drawbacks for broad vs subreceptor selective IL17 approaches. <\/p>\n - Combinations and immunosuppression <\/p>\n<\/p>\n More: DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/2r4sgn\/psoriasis_thought<\/a>) has announced the addition of the \"Psoriasis Thought Leader Panel #22 2012-04\" report to their offering. Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development. The Panel Weighs in On: - The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals Continue reading
\nResearch and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of Persepectives from 6 Key Opinion Leaders<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"